BMJ  2007;334:1337 (30 June), doi:10.1136/bmj.39259.403171.DB

News

NICE's decision on dementia drugs was "irrational," High Court is told

Clare Dyer, legal correspondent

BMJ

The first 150 words of the full text of this article appear below.

The regulatory body that decides which treatments the NHS should pay for was accused of "irrational" decision making in the High Court this week for denying drugs to patients in the mild stage of Alzheimer's disease.

The National Institute for Health and Clinical Excellence (NICE), which issues its guidance on the basis of cost benefit analyses, is facing its first legal challenge to a decision to restrict a drug's availability on the NHS.

The unprecedented case was brought to the High Court in London this week by two drug companies and by the Alzheimer's Society, representing patients and carers.

NICE's guidance last year meant that nearly 100 000 patients a year in England, Wales, and Northern Ireland with mild Alzheimer's disease were no longer entitled to certain drugs on the NHS. The drugs are the acetyl cholinesterase inhibitors donepezil (Aricept), rivastigmine (Exelon), and galantamine (Reminyl). Eisai, the Japanese manufacturer of . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Relevant Article

Care for people with dementia 50 years out of date, report says
Zosia Kmietowicz
BMJ 2007 335: 15. [Extract] [Full Text]

Rapid Responses:

Read all Rapid Responses

NICE one NICE - What about the gap in affordability?
R K Mohindra
bmj.com, 13 Aug 2007 [Full text]
Access jobs at BMJ Careers
Whats new online at Student BMJ